Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesothelin CAR-T cells + claudin 18.2 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Essen Biotech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This combination cell therapy consists of autologous T-cells engineered to express chimeric antigen receptors (CARs) targeting two distinct tumor-associated antigens: Mesothelin (MSLN) and Claudin 18.2 (CLDN18.2). Developed by Essen Biotech, the treatment involves the sequential infusion of two separate CAR-T cell products following a lymphodepleting chemotherapy regimen of fludarabine and cyclophosphamide. Mesothelin is a cell surface glycoprotein overexpressed in various solid tumors, including pancreatic cancer, while Claudin 18.2 is a tight junction protein frequently expressed in gastric and pancreatic adenocarcinomas. By targeting both antigens, the therapy aims to address tumor heterogeneity and enhance therapeutic efficacy in patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
- Other names
- Mesothelin and Claudin 18.2 CAR-T cellsDual-Target CAR-T (Mesothelin/Claudin 18.2)
02
Targets
MesothelinClaudin 18.2
Beyond the preview
Go deeper on mesothelin CAR-T cells + claudin 18.2 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesothelin CAR-T cells + claudin 18.2 CAR-T cells.